Research programme: anti-progranulin antibodies - Ligand Pharmaceuticals

Drug Profile

Research programme: anti-progranulin antibodies - Ligand Pharmaceuticals

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crystal Bioscience
  • Developer Ligand Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action PC cell-derived growth factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 27 Jul 2016 Research programme: anti-progranulin antibodies - Crystal Bioscience is available for licensing as of 27 Jul 2016.
  • 27 Jul 2016 Early research in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top